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HLA class II-restricted regulatory T cell (Treg) epitopes in IgG (also called “Tregitopes”) have been reported to suppress immune
responses to coadministered antigens by stimulating the expansion of natural Tregs (nTregs). Here we evaluate their impact on
human immune responses to islet cell antigens ex vivo and on the modulation of type 1 diabetes (T1D) in a murine model in vivo.
Co-administration of Tregitopes and T1D antigens delayed development of hyperglycemia and reduced the incidence of diabetes
in NOD mice. Suppression of diabetes could be observed even following onset of disease. To measure the impact of Tregitope
treatment on T cell responses, we evaluated the effect of Tregitope treatment in DO11.10 mice. Upregulation of FoxP3 in KJ1-26stained OVA-specific CD4+ T cells was observed following treatment of DO11.10 mice with Tregitopes, along with reductions in
anti-OVA Ig and T effector responses. In ex vivo studies of human T cells, peripheral blood mononuclear cells’ (PBMC) responses
to GAD65 epitopes in the presence and absence of Tregitope were variable. Suppression of immune responses to GAD65 epitopes
ex vivo by Tregitope appeared to be more effective in assays using PBMC from a newly diagnosed diabetic subject than for other
more established diabetic subjects, and correlation of the degree of suppression with predicted HLA restriction of the Tregitopes
was confirmed. Implementation of these defined regulatory T cell epitopes for therapy of T1D and other autoimmune diseases may
lead to a paradigm shift in disease management.

1. Introduction
Induction of antigen-specific tolerance is a logical strategy
for immunological therapy for type 1 diabetes (T1D). T1D
is an organ-specific autoimmune disease resulting from the
destruction of insulin-producing pancreatic islet beta cells.
In nondiabetics, islet antigen-specific T cells are deleted
during thymic development, rendered anergic, or converted
to regulatory T cells (Tregs) that actively suppress effector
responses to islet cell antigens. In persons with T1D and in

the non-obese diabetic (NOD) mouse model of T1D, these
tolerance-inducing mechanisms do not function properly.
In humans, defects in Tregs have been proposed as one
mechanism by which individuals develop T1D, and this defect
is said to be both functional and quantitative [1]. In the
absence of effective regulatory suppression, CD8+ and CD4+
auto-reactive T cells respond to islet antigens presented by
human leukocyte antigen (HLA) molecules. The gradual
destruction of islet cells by these auto-reactive cells eventually
leads to glucose intolerance.
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Figure 1: Postulated Tregitope mechanism of action. Tregitopes are highly conserved Treg epitopes found in human and other species’ IgG.
They are postulated to reduce the immunogenicity of neo-epitopes in the hypervariable region of IgG CDR; they also suppress immune
response to other co-delivered T cell epitopes. (A version of this figure was originally published in Blood. De Groot A. S., Moise L., McMurry
J. A., Wambre E., Van Overvelt L., Moingeon P., Scott W., Martin W. Activation of natural regulatory T cells by IgG Fc-derived peptide
“Tregitopes”. Blood 2008; 112 : 3303.)

Natural Tregs (nTregs) are an important component of
immune regulation in the peripheral circulation, suppressing
auto-reactive T cell responses to unrelated antigens by both
contact-dependent and -independent mechanisms [2].
Expansion of CD4+ CD25hi FoxP3+ nTregs is being considered as a potential novel therapy for treatment of diabetes [3].
Ideally, as described here, administration of nTregs or nTreginducing therapies in conjunction with islet cell “target antigen(s)” would convert auto-reactive T cells to adaptive Tregs,
restoring antigen-specific tolerance. Expansion of nTregs is
generally performed through non-specific means (with IL-2)
since, with few exceptions [4, 5], the antigen specificity of
nTregs is still unknown. Autoimmune responses can be modulated by nTregs by inhibiting the antigen-specific activity of
nearby auto-reactive effectors and/or by changing the phenotype of the effectors to an induced Treg (iTreg) phenotype.
We previously identified a set of Treg epitopes derived
from immunoglobulin G (IgG) that induces Tregs to
expand and leads to antigen-specific tolerance [6] (Figure 1).
We hypothesized that these Tregitopes (T regulatory cell
epitopes) are natural T cell epitopes contained in IgG; their
presence in the highly conserved domains of IgG may explain
why intravenous immunoglobulin therapy is associated with
the expansion of nTregs in mice and in humans [7, 8]. Tregitopes can be defined as peptides that (a) bind to multiple MHC
class II molecules, (b) induce Tregs to suppress effector T cell
responses to co-delivered antigen, and (c) upregulate Tregassociated cytokines and chemokines. T cells that expand

in response to Tregitopes exhibit a T regulatory phenotype
(CD4+ CD25hi FoxP3+ ) [6]. In addition to the Tregitopes that
were first described in 2008, several Tregitopes that fit the
above criteria have been identified in the Fab (framework)
and Fc regions of IgG. We and others have suggested that
Tregitopes may occur in other common serum proteins
such as albumin [9]. The Tregitopes used in the present
study include two previously described human Tregitopes
(hTregitopes), 167 and 289, and two murine homologs of
hTregitopes 167 and 289 (mTregitopes), which are located in
the CH1 and CH2 domains of IgG Fc, respectively.
Tregs are known to suppress T cell responses directly and
indirectly [10]. In concordance with existing theories about
nTregs, direct suppression of bystander T cells may be mediated by Tregitope-specific nTregs [10, 11] through expression
of certain cytokines and/or by modulation of the antigenpresenting cell (APC) towards a tolerance-inducing phenotype. Indirect suppression (not specific to the T cell epitope
or Tregitope recognized by the nTreg) would be mediated by
adaptive Tregs, also known as iTregs [2, 10]. In the present
study, we tested the ability of Tregitopes to suppress immune
responses in vivo with and without murine preproinsulin
(PPI, islet cell antigen) epitopes in the NOD model of T1D. We
also treated DO11.10 mice with Tregitopes, so as to determine
the effect on bystander effector cells in vivo, and utilized welldefined reagents to examine antigen-specific T cells from
these mice. The DO11.10 studies permitted an examination
of Tregitope effects elicited solely due to induction of nTregs
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and the subsequent induction of iTregs that, in the case of
DO11.10, would be OVA antigen specific.
If, as demonstrated here, activation of nTregs by Tregitopes and the subsequent induction of iTregs could slow or
halt the immune destruction of islet beta cells in the pancreas,
Tregitopes might be used early in diabetes as a treatment
for preserving endogenous insulin production. Moreover, the
potential for Tregitopes to induce antigen-specific tolerance
(as compared to more broadly immunosuppressive treatments) could contribute to a shift in clinical management
of autoimmune disease, away from immunosuppression and
towards antigen-specific immunomodulation.

2. Materials and Methods
2.1. In Silico Immunoinformatics Methods
2.1.1. EpiMatrix. EpiMatrix is a T cell epitope-mapping algorithm that is used to identify putative HLA ligands/T cell
epitopes, such as Tregitopes, contained within protein sequences (e.g., epitopes identified from pathogen genomes in
references [12, 13]). Computation is performed by comparing
peptide sequences with a set of HLA allele-specific coefficient
matrices. To complete an analysis using the EpiMatrix algorithm, target protein sequences are parsed into overlapping
9-mer frames in which each frame overlaps the last by eight
amino acids. Each amino acid in the 9-mer is then assigned a
positive or negative coefficient based on its previously determined propensity to positively or negatively impact peptide
binding when located at that amino-acid position within the
HLA-binding groove [14]. The coefficients are then summed
to produce a raw score for each 9-mer. Raw scores are
normalized with respect to a distribution derived from a large
set of randomly generated peptide sequences. The resulting
Z-scores from this distribution are directly comparable across
predictions for different alleles.
2.1.2. ClustiMer. By performing this operation repeatedly on
a large range of protein sequences, from pathogens to autologous proteins, we have determined that T cell epitopes are
not randomly distributed throughout protein sequences but
instead tend to “cluster” together within a protein sequence
[15]. T cell epitope “clusters” range from 12 to roughly 25
amino acids in length and can contain anywhere from four
to 40 binding motifs in the overlapping 9-mer frames. ClustiMer preferentially identifies epitope clusters restricted by
multiple HLA class II alleles covering 95% of human populations [16]; clusters selected in this manner demonstrate
strong HLA binding affinity and T cell responses [13, 17–
19]. Many of the most immunogenic T cell epitope clusters
contain a feature we now refer to as an EpiBar [20]. An EpiBar
is a single 9-mer frame that is predicted to be reactive to at
least four different HLA alleles. Peptides containing EpiBars
appear to have a greater-than-expected ability to induce T cell
responses of either a stimulatory or suppressive phenotype.
This may be due to the co-location of strong HLA binding
motifs [12, 13].

3
2.1.3. Selection of GAD65 Epitopes and Clusters. Based on EpiMatrix analysis of GAD65, we selected 14 peptides containing
EpiBars for in vitro HLA binding assays and T cell assays
using peripheral blood mononuclear cells (PBMC) from T1D
subjects. The human GAD65 sequence was obtained from
the GenBank sequence database at the National Center for
Biotechnology Information (NCBI: Accession Q05329). This
sequence was parsed into 577 overlapping 9-mers and scored
for predicted HLA binding affinity using the EpiMatrix
algorithm as previously described [21, 22]. Figure 2 illustrates
the locations of GAD65 clusters (highlighted in shades of
red that correspond with overall EpiMatrix score) selected by
EpiMatrix, as well as a comparison between EpiMatrix predictions and T1D epitopes published in a recent compendium
(in blue [23]). Details of the sequences tested in vitro are also
provided in greater detail in Table 1.
Figures 3(a) and 3(b) provide more detailed EpiMatrix
cluster reports for two GAD65 peptides. “EpiBars” are present
in these peptides. For the cluster located at amino acid
position 450 (GAD65 450, Figure 3(a)), one EpiBar begins at
Frame 455, a second starts at 456, and a third (weaker due
to lower overall scores) at 459. This GAD65 sequence has
not previously been identified or published as an epitope. As
illustrated in Figures 2 and 3(b), there are published GAD65
epitopes located in peptide GAD65 550 at frame 557; the same
sequence contains an EpiBar.
2.1.4. iTEM Analysis. The iTEM (Individualized T cell Epitope Measure) tool provides an estimate as to whether a given
individual will develop a T cell response to a protein antigen,
based on HLA binding predictions. We use a mathematical
formula that converts DRB1 allele binding predictions generated by EpiMatrix into an allele-specific scoring system. Thus,
iTEM can be used to define an HLA binding threshold, above
which immune response is likely to be present and below
which immune response is likely to be absent for individual
study subjects. iTEM scores have been shown to correlate
with immune responses to peptides in T cell assays in vitro
[24]. An iTEM score was calculated for each of the Tregitope
peptides, and the result was compared to in vitro responses
generated in the two-step ELISpot assay.
2.2. Peptides and Peptide Synthesis. All peptides used in
this study were synthesized by 9-fluoronylmethoxy-carbonyl
(Fmoc) synthesis to a purity of >80% as determined by
HPLC by New England Peptide (Gardner, MA, USA) and 21st
Century Biochemicals (Marlborough, MA, USA). The peptide masses were confirmed using either a Q-Star nanospray
Mass Spectrometer (New England Peptide) or by MALDITOF mass spectrometry (21st Century Biochemicals). Third
party QC was performed by Cell Essentials (Cambridge,
MA, USA). Tregitope peptides are as previously described
[6]; murine Tregitopes 167 and 289 are as described in
Elyaman et al. [25]. Tregitope sequences, murine PPI peptide
sequences, and class II-binding control peptide sequences
are listed in Table 2. Murine Tregitopes 167 and 289 each
contain a single significant score (1.98 and 1.73, resp.) for the
murine class II MHC allele I-Ag7 (NOD) based on in silico

196

190

180

170

160

150

140

130

120

110

100

90

80

70

60

50

40

30

1

20

Journal of Diabetes Research
10

4

MASPGSGFWSFGSEDGSGDSENPGTARAWCQVAQKFTGGIGNKLCALLYGDAEKPAESGGSQPPRAAARKAACACDQKPCSCSKVDVNYAFLHATDLLPACDGERPTLAFLQDVMNILLQYVVKSFDRSTKVIDFHYPNELLQEYNWELADQPQNLEEILMHCQTTLKYAIKTGHPRYFNQLSTGLDMVGLAADWL

86–103 : 11.6

114–134 : 13.4

175–190 : 10.1

NOD
∗
∗

0401
0101

∗

0301
0701
0801
∗
1101
∗
1301
∗
∗

390

380

370

360

350

340

330

320

310

300

290

280

270

260

250

240

230

220

210

1501

200

∗

TSTANTNMFTYEIAPVFVLLEYVTLKKMREIIGWPGGSGDGIFSPGGAISNMYAMMIARFKMFPEVKEKGMAALPRLIAFTSEHSHFSLKKGAAALGIGTDSVILIKCDERGKMIPSDLERRILEAKQKGFVPFLVSATAGTTVYGAFDPLLAVADICKKYKIWMHVDAAWGGGLLMSRKHKWKLSGVERANSVTW

210–232 : 15.4

242–267 : 16.7

324–342 : 11.5

354–372 : 14.8

264–284 : 12.25

368–392 : 19.2

NOD
∗
∗

0401
0101

∗

0301
0701
0801
∗
1101
∗
1301
∗
∗

580

570

560

550

540

530

520

510

500

490

480

470

464

460

450

440
443

430

420

410

1501

400

∗

NPHKMMGVPLQCSALLVREEGLMQNCNQMHASYLFQQDKHYDLSYDTGDKALQCGRHVDVFKLWLMWRAKGTTGFEAHVDKCLELAEYLYNIIKNREGYEMVFDGKPQHTNVCFWYIPPSLRTLEDNEERMSRLSKVAPVIKARMMEYGTTMVSYQPLGDKVNFFRMVISNPAATHQDIDFLIEEIERLGQDL

444–470 : 33.2

550–570 : 22.0

NOD
∗
∗

0401
0101

∗

0301
0701
0801
∗
1101
∗
1301
∗
∗

∗

1501

Figure 2: Map of GAD65 epitopes performed using EpiMatrix. EpiMatrix-predicted epitopes are shown in shades of grey and black; darker
colors denote stronger binding potential. Published human epitopes are in bright blue. Clusters are identified in shades of yellow-orangered; again, stronger colors (more red) denote higher predicted immunogenicity. Previously published NOD epitopes are shown in green.
The clustering of predicted (and published) epitopes is clearly illustrated for EpiMatrix-predicted epitope clusters 450–470 (shown in greater
detail in Figure 3(a)) and 550–570 (Figure 3(b)).

analysis using an EpiMatrix experimental predictive matrix.
Irrelevant control peptide TetTox831–845 contained slightly
lower predicted binding scores for the NOD MHC allele
(maximum score of 1.51).

Vesicles <150 nm in diameter were produced by 20–30 cycles
of extrusion through polycarbonate filters using a Liposofast
extruder (Avestin, Canada). Liposome formulations were
stored at 4∘ C until use.

2.3. Liposome Preparation. Sterically stable cationic liposomes were prepared from three lipid components: dioleylphosphatidylethanolamine (DOPE), dimethylaminoethanecarbamoyl-cholesterol (DC-cholesterol), and polyethylene
glycol 2000-phosphatidyl-ethanolamine (PEG). The lipids
were mixed, dried in a rotary evaporator, and resuspended
in phosphate-buffered saline (PBS; Sigma-Aldrich, St. Louis,
MO, USA) to make empty multi-lamellar vesicles. These
vesicles were sonicated five times for 30 seconds each at 4∘ C
to convert them into unilamellar liposomes. Unilamellar liposomes (10 nmol) were mixed with peptides, flash frozen, and
freeze-dried overnight. To encapsulate peptides in liposomes,
the resulting powder was resuspended with sterile distilled
water and vortexed for 15 seconds every five minutes for
30 minutes at room temperature. PBS was added to yield
a final liposome concentration of 10 mM lipid/mg peptides.

2.4. In Vivo Study Methods
2.4.1. Mouse Models. Non-obese diabetic (NOD/ShiLtJ)
mice, a polygenic model for T1D, were purchased from the
Jackson Laboratory (Bar Harbor, ME, USA). NOD/ShiLtJ
mice exhibit diabetes beginning at around 12 weeks of age,
characterized by insulitis, a leukocytic infiltrate of the pancreatic islets [26]. Plasma glucose levels are used to determine
disease onset. T cell receptor (TCR) transgenic DO11.10/
FoxP3-GFP and DO11.10/FoxP3-GFP/Rag2−/− were developed as described in [27]. Briefly, a FoxP3-GFP mouse was
crossed against a line of either DO11.10 or DO11.10/Rag2−/−
mice and backcrossed to create homozygous DO11.10/FoxP3GFP lines. All animals were housed and bred in pathogenfree micro-isolator cages at the animal facilities operated by
the University of Maryland School of Medicine.
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EpiMatrix cluster detail report
GAD65 position 450–470

Frame
start

AA
sequence

450
451
452
453
454
455
456
457
458
459
460
461
462

VDVFKLWLM
DVFKLWLMW
VFKLWLMWR
FKLWLMWRA
KLWLMWRAK
LWLMWRAKG
WLMWRAKGT
LMWRAKGTT
MWRAKGTTG
WRAKGTTGF
RAKGTTGFE
AKGTTGFEA
KGTTGFEAH

Total assessments
performed: 104

Frame DRB1∗ 0101 DRB1∗ 0301 DRB1∗ 0401 DRB1∗ 0701 DRB1∗ 0801 DRB1∗ 1101 DRB1∗ 1301 DRB1∗ 1501
stop
Z score
Z score
Z score
Z score
Z score
Z score
Z score
Z score
458
1.64
459
460
461
2.62
2.61
462
463
1.82
2.41
2.53
2.83
464
2.26
2.01
3.07
1.81
1.48
465
1.72
1.86
466
1.64
1.69
467
1.67
1.81
2.18
1.71
1.78
1.62
1.74
1.54
468
469
1.84
470
Hydrophobicity: 0.03

EpiMatrix score: 30.4

Hits
0
0
0
2
0
4
4
2
1
6
0
1
0

EpiMatrix cluster score (𝑤/𝑜 ﬂanks): 33.9

(a)

EpiMatrix cluster detail report
GAD65 position 550–570
AA
Frame
start sequence
550 LGDKVNFFR
551 GDKVNFFRM
552 DKVNFFRMV
553 KVNFFRMVI
554 VNFFRMVIS
555 NFFRMVISN
556 FFRMVISNP
557 FRMVISNPA
558 RMVISNPAA
559 MVISNPAAT
560 VISNPAATH
561 ISNPAATHQ
562 SNPAATHQD
Total assessments
performed: 104

∗
∗
∗
∗
∗
∗
∗
∗
Frame DRB1 0101 DRB1 0301DRB1 0401 DRB1 0701 DRB1 0801 DRB1 1101DRB1 1301 DRB1 1501
Z score
Z score
Z score
Z score
Z score
Z score
Z score
Z score
stop
558
559
560
561
1.76
1.64
2.24
562
1.63
563
564
1.30
1.57
1.62
565
2.68
2.32
3.24
2.75
1.91
2.54
1.69
2.97
566
567
1.87
1.75
1.50
1.44
1.47
568
1.38
1.55
1.70
1.28
569
570

Hydrophobicity: −0.23

EpiMatrix score: 17.87

Hits
0
0
0
2
0
0
0
8
0
2
1
0
0

EpiMatrix cluster score (𝑤/𝑜 ﬂanks): 22.32

(b)

Figure 3: GAD65 450–470 and 550–570 cluster maps. EpiMatrix-predicted 9-mer hits for eight prevalent HLA class II alleles are shown in
the cluster map under each allele for two example GAD 65 peptide sequences. Any 9-mer peptide scoring above 1.64 on the EpiMatrix “Z”
scale (top 5%) is considered to be a potential epitope (blue bars) or “hit.” Peptides scoring above 2.32 on the scale (top 1%) are extremely likely
to bind MHC (dark blue bars). The 450–470 cluster contains three 9-mers with multiple positive scores. Hits across four or more HLA class
II alleles constitute an EpiBar. The GAD65 450–470 cluster contains three EpiBars; the 550–570 cluster contains a single EpiBar (highlighted
in yellow).

2.4.2. Immunizations. Groups of female mice were immunized with either peptides or protein in one of several delivery
vehicles: PBS, incomplete Freund’s adjuvant (IFA; SigmaAldrich), or liposomes (described above). Immunizations
were given as indicated for each of the experiments, either
intraperitoneally or in one hind footpad by needlestick.
Additional experimental details are provided in the section
devoted to each of the assays.
2.4.3. T Cell Phenotyping and Proliferation Assays (DO11.10).
Draining inguinal and popliteal nodes were harvested and the
samples were evaluated by FACS for T cell proliferation and

Treg expansion. The KJ1-26 mAb that reacts with the clonotypic TCR expressed by DO11.10 transgenic mice was used
to identify T cells expressing the transgenic OVA-specific
TCR. To detect FoxP3/GFP+ Tregs, a single-cell suspension of
draining lymph nodes was incubated with 2.4G2 mAb (antiCD16/32, ATCC) for 15 minutes to block FcR, then stained
with CD4-PE and anti-clonotypic KJ1-26-APC for 40 minutes
at 4∘ C. Cells were acquired on a FACSCalibur flow cytometer
(Becton-Dickinson, Franklin Lakes, NJ, USA) and analyzed
using FlowJo software (Treestar, Ashland, OR, USA). The
CD4+ KJ1-26+ live cell gate population was established, and
these gated cells were analyzed for the presence of GFP
fluorescence indicative of FoxP3 expression.

Peptide Name
Sequence
GAD65 086–103 DVNYAFLHATDLLPACDG
GAD65 175–190 HPRYFNQLSTGLDMVG
GAD65 203–226 NMFTYEIAPVFVLLEYVTLKKMRE
GAD65 243–267 GAISNMYAMMIARFKMFPEVKEKGM
GAD65 264–287 EKGMAALPRLIAFTSEHSHFSLKK
GAD65 338–352 TTVYGAFDPLLAVAD
GAD65 354–372 CKKYKIWMHVDAAWGGGLL
GAD65 369–392 GGLLMSRKHKWKLSGVERANSVTW
GAD65 405–424 SALLVREEGLMQNCNQMHAS
GAD65 450–470 VDVFKLWLMWRAKGTTGFEAH
GAD65 480–496 YLYNIIKNREGYEMVFD
GAD65 504–518 VCFWYIPPSLRTLED
PSLRTLEDNEERMSR
GAD65 511–525
GAD65 550–570 LGDKVNFFRMVISNPAATHQD

EpiMatrix Cluster Score
12.19
9.98
14.70
15.87
13.77
9.69
14.48
17.60
4.45
33.90
5.90
7.58
−0.89
22.32

DRB1∗ 0101 IC50
<5
10.7
—
<5
—
4.1
NB
16.3
NB
25.4
<5
95.8
NB
—

DRB1∗ 0401 IC50
7.5
>50
<25
NB
<25
NB
6.4
<5
>50
NB
5.7
NB
NB
<25

DRB1∗ 0701 IC50
<5
13.9
—
8.7
—
NB
<5
<5
NB
10.2
NB
25.2
NB
—

DRB1∗ 1501 IC50
NB
NB
—
<5
—
31.3
>50
NB
NB
11.4
<5
10.3
NB
—

Published?
Y (NOT DR4)
N
Y (NOT DR4)
Y (NOT DR4)
Y
Y (NOT DR4)
Y
Y
Y (NOT DR4)
N
Y
Y
Y
Y

Table 1: GAD65 sequences and HLA binding IC50 . Sequences for GAD65 epitopes were predicted using EpiMatrix (for high cluster score and if possible for high predicted HLA DR4 binding
affinity) and synthesized for testing in HLA binding assays. The calculated IC50 values (𝜇M) for four HLA alleles are provided. “NB” indicates the peptide was a non-binder. The peptides
were predicted and confirmed to be promiscuous binders (see Figure 2).
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Table 2: Treatment and control peptides for in vitro and in vivo studies. The following table contains information on the sequences, MHC
promiscuity, and parental protein location of the peptides and controls used in these studies.
Peptide name
Amino acids
hTregitope IgG-167
26
hTregitope IgG-289
21
mTregitope IgG-167
20
mTregitope IgG-289
18
mPPI 7–23
17
mPPI 20–35
16
mPPI 33–47
15
mPPI 71–86
16
mPPI 77–92
16
TetTox 830–844
15
Flu-HA 308–318
13
OVA 323–339
17

Sequence
PAVLQSSGLYSLSSVVTVPSSSLGTQ
EEQYNSTYRVVSVLTVLHQDW
PAVLQSDLYTLSSSVTVPSS
EEQFNSTFRSVSELPIMHQ
FLPLLALLALWEPKPTQ
KPTQAFVKQHLCGPHL
PHLVEALYLVCGERG
SPGDLQTLALEVARQK
TLALEVARQKRGIVDQ
QYIKANSKFIGITEL
PRYVKQNTLKLAT
KISQAVHAAHAEINEAG

Antigen-specific T cell proliferation was evaluated by
[3 H] thymidine incorporation [27]. Draining lymph nodes
were harvested and a single-cell suspension was prepared at
2 × 106 cells/mL. Cells were added to 96-well plates at 100 𝜇L
per well in the presence of indicated concentration of OVA
323–339 (New England Peptide, Gardner, MA, USA). Fortyeight hours later, the cells were pulsed with 1 𝜇Ci/well of [3 H]
thymidine and incubated for another 16–20 hours. Cells were
then harvested on glass fiber filters, and [3 H] incorporation
into the DNA was measured using a MicroBeta2 plate
counter.
2.5. In Vitro Study Methods
2.5.1. HLA Binding Assays. Of the 16 GAD65 peptides selected for this study, 14 could be synthesized and purified to
≥80% pure; GAD65 324-342 was not included in the studies
reported here due to technical difficulties in peptide synthesis, and GAD65 108-131 was not included due to low purity.
Therefore, we validated 14 epitopes in HLA-DR binding
studies for use in ex vivo two-step ELISpot assays with human
PBMC.
Human Tregitopes and GAD65 epitopes were evaluated
for binding to HLA in vitro. We used an HLA binding assay
initially described by Steere et al. [28] and adapted for higher
throughput in our laboratory. In 96-well plates, a test peptide
and a reference peptide competed for binding to purified class
II HLA molecules (provided by William Kwok, Benaroya
Institute, Seattle, WA, USA) for 24 hours at 37∘ C. The nonbiotinylated test peptides were evaluated over a range of concentrations, while the biotinylated reference peptide was held
at a fixed concentration (0.1–1 𝜇M depending on the HLA).
The reference peptides and concentrations were as follows:
biotin-Flu-HA 306–318 (PRYVKQNTLKLAT) at 0.1 𝜇M for
DRB1∗ 0101 and DRB1∗ 0401, and at 1 𝜇M for DRB1∗ 0701; and
biotin-MBP 84–102 (NPVVHFFKNIVTPRTPPPS) at 0.5 𝜇M
for DRB1∗ 1501. The peptides that bound to class II molecules
were then captured on ELISA plates using pan anti-class II

HLA motifs
20
14
n/a
n/a
11
2
3
0
2
13
10
4

EpiMatrix cluster score
30.05
22.57
n/a
n/a
18.69
−2.82
−0.69
−6.59
−3.1
25.65
21.82
−0.39

Location in IgG
CH1
CH2
CH1
CH2
—
—
—
—
—
—
—
—

antibodies (L243, anti-HLA-DR alpha chain). The assays were
developed by addition of streptavidin-europium and read
on a time-resolved fluorescence plate reader. Standard curve
analysis using four-parameter logistics was performed in
SigmaPlot software, and an IC50 value was calculated for each
peptide-allele pair in which 50% inhibition was encompassed
by the range of test peptide dilutions (Table 1). Some peptides
were available in limited supply and thus were only tested for
binding to DRB1∗ 0401.
2.5.2. Study Subjects. Subjects diagnosed with T1D and who
possessed the HLA-DR4 allele were recruited at the Hallett
Center for Diabetes and Endocrinology, Rhode Island Hospital (Providence, RI, USA). Negative control subjects were
recruited under a separate IRB protocol in collaboration with
Dr. William Beliveau of Clinical Partners LLC (Johnston, RI,
USA). These human studies were conducted in conformance
with local institutional review board guidelines.
2.5.3. Human PBMC Two-Step T Cell Assays. PBMC from
individual subjects were isolated from whole blood using
Ficoll gradient separation. The buffy coat was washed in PBS
and resuspended in RPMI containing 10% human AB serum
(Valley Biomedical, Winchester, VA, USA), 1% L-glutamine
(Sigma-Aldrich) and 0.1% gentamycin (Sigma-Aldrich). All
cells were prestimulated with a pool of up to 14 peptides
derived from GAD65 at 2.5 𝜇g/mL per peptide as well as
exogenous IL-2 (10 IU/mL) and IL-7 (20 ng/mL), and half
were also treated with 5 𝜇g/mL each of human Tregitopes 167
and 289. The cells were plated at a density of 2.5 × 106 viable
cells/mL and cultured for 7 days in 24-well culture plates
containing 2 mL PBMC suspension in each well. Every 23 days during this period, half of the medium was replaced
with fresh medium containing IL-2 and IL-7. At the end
of the primary incubation (step 1), the cells were harvested
and restimulated in ELISpot plates (step 2) with individual
GAD65 epitopes, the peptide pool, or whole GAD65 protein
(Kronus, UK).
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Blood glucose (mg/dL)

2.5.4. ELISpot Analysis (Human PBMC). The frequency of
epitope-specific T lymphocytes was determined using
Mabtech IFN𝛾 ELISpot plates (Mabtech, Sweden). After the
initial expansion in culture (step 1), cells were washed three
times, transferred to ELISpot plates at 200,000–250,000 cells
per well, and incubated at 37∘ C for 48 hours with individual
peptides, peptide pools, or whole GAD65 protein in
triplicate (step 2). A negative control (no stimulus) and
mitogen control (PHA) were included. Spot counts were
determined by a third-party vendor (Zellnet Consulting,
Inc., Fort Lee, NJ, USA) using a Zeiss ELISpot plate reader
(Table 3). Responses were considered to be positive if two
criteria were satisfied: (1) the average number of spots in
the triplicate test wells was at least twice the average of the
background wells, and (2) the average number of spots
was at least 50 spots per 1 million cells over background.
Due to variability in amounts of blood obtained from study
subjects, cell yields following separation of PBMC from
whole blood, and recovery after the primary culture, not
all subject PBMC samples were tested with every GAD65
peptide in the ELISpot assays, as indicated by “ND.” Reduced
spot counts in Tregitope-treated cultures, as summarized
in Table 4, were tested for statistical significance, relative to
the corresponding spot counts generated by cells not treated
with Tregitopes, by a one-tailed Student’s t-test performed
on the pair of ELISpot triplicates.
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Figure 4: Study 1—prevention of T1D in NOD mice using Tregitopes. Tregitopes in saline, given IP prior to onset of diabetes, had a
moderately suppressive effect on development of diabetes in NOD
mice. The incidence of diabetes for each arm is shown along the
course of the study beginning at the first week that the mice received
treatment. Arrows represent time points when Tregitope treatment
was administered. Mice receiving vehicle alone (white circles) or
irrelevant peptide (gray circles) had a higher incidence of diabetes
at 29 weeks of age than mice receiving Tregitope treatment (black
circles).

3. Results
3.1. In Vivo Study Results
3.1.1. Tregitope Treatment of NOD Mice Prior to Onset of Diabetes. The objective of the in vivo studies was to determine
whether Tregitopes co-administered with or without mPPI
peptides could prevent the onset of diabetes in the wellcharacterized NOD murine model of spontaneous autoimmune diabetes. In the first prevention study, we dosed female
NOD mice three times intraperitoneally (i.p.) at 9, 10, and
11 weeks of age (female; 10 mice/group, 3 groups total) with
either (1) an irrelevant OVA peptide (control peptide, 100 𝜇g
per animal) delivered in saline, (2) saline control, or (3)
mTregitope 289 and mTregitope 167 in saline (50 𝜇g per
Tregitope peptide, 100 𝜇g total per animal). Blood glucose
(BG) levels were measured twice weekly for up to 30 weeks;
the mice were considered to be diabetic if their BG level was
≥250 mg/dL for two consecutive measurements.
Treatment with Tregitopes alone (without the addition
of islet cell antigen peptides) administered i.p. at 9, 10, and
11 weeks of age had a moderately suppressive effect on the
development of diabetes in NOD mice (Figure 4). Among
all 3 groups of mice tested in this experiment, BG levels
began to increase around 11 to 13 weeks of age; some mice
became diabetic at weeks 11-12. Administration of the two
Tregitopes (mTregitope 167 and mTregitope 289) reduced the
incidence of diabetes and average BG levels as compared to
the two control groups (OVA peptide and saline treatment);
this effect became apparent starting at weeks 16-17 and lasted
for the duration of the study (to week 29). These results were

not statistically significant although trends were evident and
consistent with follow-up studies, as discussed below.
In the second prevention study, NOD mice (female; 8
mice/group) were divided into five treatment groups (A–E),
each of which received five injections (at the onset of disease
in weeks 8–10, and again in weeks 14-15) of their respective
treatment. In this study, we administered Tregitopes with
the T1D-associated murine preproinsulin (mPPI) epitopes
to determine whether Tregitopes alone or Tregitopes in
conjunction with target antigen led to a better outcome.
Group A (mPPI) received the five murine PPI peptides
listed in Table 2 in liposomes; Group B (mPPI + Tregitopes)
received mPPI peptides plus four Tregitope peptides (h167,
h289, m167, and m289) in liposomes; Group C (mPPI + Tet
Tox) received mPPI peptides with a control peptide (MHCbinding tetanus toxin peptide 830–844) in liposomes; Group
D (Tregitopes) received four Tregitope peptides alone in
liposomes; and Group E (Liposomes) received empty liposomes. Tregitopes were dosed at 50 𝜇g per mouse per Tregitope peptide, for a total of 200 𝜇g per mouse. mPPI peptides
were dosed at 10 𝜇g/mouse per peptide, for a total of 50 𝜇g
per mouse. Tet Tox was administered at 200 𝜇g per mouse.
BG was measured as described above. All treatments were
started prior to onset of disease (weeks 8–10) and continued
for a total of five treatments.
Treatment with mPPI and mouse and human Tregitopes
167 and 289 suppressed the development of T1D in NOD
mice (Figure 5). None of the mice treated with Tregitope +
mPPI peptides (Group B) developed diabetes, although half

≥50 SFC over BG/106 .
<50 SFC over BG/106 .
∗
𝑃 < 0.05.
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𝑃 < 0.01.
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ND
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287
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76
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4
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8
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−
+
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4
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−
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−14
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+
155
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23
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ND
ND
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138
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591
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Negative Control 672
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−
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−98
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0
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8
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5
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ND
ND
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ND
ND
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−10
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−27
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ND
ND
ND
ND
ND
ND
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+
22
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−13
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ND
ND
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ND
ND
ND
ND
ND
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ND
ND
ND
ND
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Table 3: Two-step assay results. Diabetic and healthy subject PBMCs were incubated for 7 days with a pool of GAD65 epitopes with or without Tregitopes. The cells were then washed and
put into ELISpot plates to test recall responses to individual epitopes, the same pool used in the primary culture, or whole GAD65 protein. ELISpot results were considered positive if the
number of SFC over background per million cells was >50 (Bold). Spot counts that failed to meet this threshold were considered negative results (Italic). Due to variable PBMC yield and
recovery after 7 days, not all epitopes were included in every ELISpot, as indicated by “ND”.
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Table 4: Summary of responses of diabetic subjects to Tregitopes in
vitro. Effects of Tregitopes on ELISpot responses to the panel GAD65
epitopes, as reported in detail in Table 3, are summarized here. In the
two-step T cell assays, IFN𝛾 ELISpot responses to GAD65 peptides
were suppressed for 78% of the peptides tested using diabetic subject
PBMC and for 74% of the peptides tested using normal control
subjects. The suppression reached statistical significance for more
than a quarter (26%) of all assays performed.
Number of
Subject
peptides tested
ID
in ELISpot

Responses
suppressed by
Tregitopes

Responses suppressed
significantly
(𝑃 < 0.05)

D1100H
D1101H
D1104H
D1105H
D1106H
D1107H

9
14
14
11
12
7

6 (67%)
12 (86%)
11 (79%)
8 (73%)
8 (67%)
7 (100%)

2 (22%)
4 (29%)
3 (21%)
4 (36%)
2 (17%)
3 (43%)

N668C
N669C
N670C
N672C
N674C

10
11
11
8
14

9 (90%)
10 (91%)
11 (100%)
1 (13%)
9 (64%)

4 (40%)
3 (27%)
4 (36%)
0 (0%)
3 (21%)

(50%) of the mice treated with mPPI peptides alone (Group
A) became diabetic.
The suppression of diabetes incidence by Tregitopes was
long lasting. At 20 weeks, mice treated with Tregitopes +
mPPI (Group B) remained diabetes-free and showed no
significant glucose elevation (𝑃 < 0.01). Two mice in Group
D (Tregitopes) developed diabetes nearly two weeks before
any other group, but by the end of the study had a lower
overall incidence and lower levels of BG than any other group
except for Group B. The three groups that did not receive
any Tregitope treatment (Groups A, C, and E) all had an
incidence of diabetes above 50% at 20 weeks and average BG
measurements above 350 mg/dL.
3.1.2. Tregitope Treatment of NOD Mice following Onset of
Disease. The objective of the remaining two studies was to
determine whether Tregitopes administered at the onset of
diabetes could resolve hyperglycemia in the NOD model.
Female NOD mice were monitored for BG daily and entered
into treatment groups when BG levels were between 200–
250 mg/dL on two successive days. Upon entry into the study,
mice received a single injection of mTregitopes 167 and 289
(total 20 𝜇g) formulated in IFA in the flank by subcutaneous
injection. Control mice received PBS in IFA (as a vehicle
control) or were left untreated. BG levels were measured
weekly following the treatment up to 30 weeks, and mice were
considered to be diabetic if their BG level was ≥250 mg/dL.
The experiment was conducted twice.
As shown in Figure 6(a), a single Tregitope-IFA treatment reduced BG over a period of 25 weeks in the first
of these experiments. PBS-IFA controls exhibited initial
suppression, but an eventual rise of BG was observed in
the majority of mice. The group that received Tregitopes in
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Figure 5: Study 2—prevention of T1D in NOD mice using Tregitopes. When co-administered with the “target” antigen (five murine
preproinsulin or mPPI peptides) in liposomes, treatment with four
Tregitope peptides (mouse 167 and 289 and human 167 and 289)
completely suppressed the development of T1D in NOD mice.
Arrows represent time points when treatments were administered.
Black symbols represent groups receiving Tregitopes with (circle)
or without (square) target antigen. White circles represent the
vehicle control group. Antigen peptides alone are indicated by white
triangles, and antigen peptides with an irrelevant MHC-binding
peptide by gray circles. Mice receiving liposomes alone (white
circles) had a 67% incidence of diabetes at 20 weeks of age compared
to 38% in mice receiving Tregitopes alone (black square). None of
the mice receiving Tregitopes with antigen (black circles) developed
diabetes.

IFA had a stronger and longer-lasting effect. By 25 weeks
on study (approximately 35 weeks of age), seven of twelve
(58%) Tregitope-treated diabetic mice had reduced BG from
greater than 250 to normal levels and remained non-diabetic,
whereas only two of nine (22%) PBS controls remained nondiabetic, and all twelve (100%) untreated mice had developed
diabetes within two weeks. When the percentages of diabetesfree mice in each group were plotted over time as KaplanMeier curves and analyzed using the log-rank test and
pairwise Holm-Sidak comparisons, there was a significant
(𝑃 ≤ 0.005) difference between the untreated and Tregitopetreated groups, but not between the PBS-IFA and Tregitopetreated groups.
In the second experiment (Figure 6(b)) all untreated
control mice rapidly progressed, reaching BG of 500 mg/dL
within 2-3 weeks. In the group of mice that received
Tregitope-IFA, ten of eleven (91%) mice had BG less than
250 mg/dL at 26 weeks on study (approximately 36 weeks
of age), and four (36%) of these had transient elevations
that self-corrected, suggesting that there was a long-lasting
effect of the Tregitope treatment on immune homeostasis. In
general, mice for which treatment was initiated when their
BG was greater than 350 mg/dL did not respond to Tregitope
treatment. In the PBS-IFA group, three of seven (43%) mice
had BG lower than 250 mg/dL at the end of 20 weeks on
study (30 weeks of age), suggesting that IFA alone may have
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and both untreated and PBS-IFA-treated groups by the HolmSidak method.
If the two experiments are combined, seventeen of 23
(74%) of the initially diabetic mice in the Tregitope-IFA group
had BG lower than 250 mg/dL at the end of observation. In
contrast, only five of sixteen (31%) mice treated with vehicle
alone (PBS in IFA) had a BG level lower than 250 mg/dL at
the end of 20 weeks, suggesting Tregitopes delivered by depot
injection (in IFA) at the onset of disease are able to reverse
new-onset diabetes in NOD mice.
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Figure 6: Treatment with Tregitopes in IFA at onset of diabetes.
Female NOD mice were monitored for blood glucose (BG) levels.
Disease onset was defined as BG between 200 and 250 mg/dL
measured on two consecutive days, at which time mice were entered
into the study. Mice received a single subcutaneous injection in the
flank of either mTregitopes 167 and 289 (total 20 𝜇g) formulated in
IFA or PBS in IFA (as a vehicle control) or they were left untreated.
BG levels were then measured weekly. In the initial study (a),
Tregitopes suppressed the progression of diabetes in seven of twelve
mice, whereas IFA alone had less of an effect. This study was repeated
(b), showing successful “cure” of diabetes after onset. All pair-wise
comparisons are significant (𝑃 ≤ 0.05).

a partial effect on the development of diabetes. Nonetheless,
there were significant (𝑃 ≤ 0.05) differences in diabetes-free
percentages over time between the Tregitope-treated group

3.1.3. Antigen-Specific Adaptive Tolerance Induction. Antigen specificity could not be measured in the NOD model
as reagents (antibodies staining TCR specific for islet cell
antigens and tetramers for NOD mouse epitopes) were not
available at the time these studies were performed. Instead,
DO11.10 mice, a TCR transgenic (Tg) line in which the
TCRs are specific for a peptide derived from the ovalbumin
antigen (OVA), were employed to further examine effects of
Tregitope on the induction of adaptive tolerance in vivo. In
these mice, approximately 80% of CD4+ cells, of which 3–
5% are naturally FoxP3+ , possess a Tg TCR that is specific for
OVA 323–339 peptide and recognized by the anti-clonotype
mAb KJ1-26. The other 20% of CD4+ T cells, of which 10–15%
are FoxP3+ , have endogenously recombined TCRs.
Six DO11.10 FoxP3/GFP knock-in Tg mice (generated
from mice purchased from Jackson Laboratories as described
in methods and in [27]) were each injected with 15 𝜇g of
mTregitopes 167 and 289; five control DO11.10 FoxP3/GFP
knock-in Tg mice were injected with an equivalent amount
of MHC-binding irrelevant control peptide from influenza
hemagglutinin (Table 2, Flu HA 306–318), emulsified in IFA
via one hind footpad. After 10 days, mice were sacrificed and
draining inguinal and popliteal lymph nodes were removed
for T cell isolation. We measured (i) suppression of OVAspecific proliferative T cell responses to stimulation with
OVA 323–339 peptide ex vivo by [3 H] thymidine incorporation assay and (ii) induced GFP (FoxP3) expression in the
CD4+ /KJ1-26+ T cells by FACS after staining.
As shown in Figure 7, Tregitope treatment suppressed
OVA-specific proliferative T cell responses to OVA 323–339
peptide as compared to the control (Flu HA) and increased
proportions of FoxP3-expressing CD4+ T cells bearing the
OVA-specific Tg TCR (KJ1-26+ ). Of the CD4+ Tg T cells,
more than 8% were FoxP3+ (𝑃 < 0.02 as compared to Flu HA
control). This significant increase in FoxP3-GFP+ /KJ1-26+
cells demonstrates adaptive tolerance induction, as the Tregitopes presented in murine MHC cannot be recognized directly
by the OVA-peptide specific Tg T cells. A similar experiment
was performed in Rag−/− DO11.10 mice, which have OVAspecific T cells but lack endogenous TCR and therefore
would lack Tregitope-specific nTregs. No suppression of ex
vivo proliferation or IFN𝛾 production was observed in this
context (data not shown), suggesting that Tregitope-specific
nTregs are required for Tregitope treatment-associated iTreg
induction.
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determined in other proteins, GAD65 T cell epitopes identified by EpiMatrix are not randomly distributed throughout
the protein sequence but instead tend to “cluster” in specific
regions, which overlap with previously published epitopes
(Figure 2 and Table 1). The T cell epitope clusters range from
twelve to roughly 25 amino acids in length and contain up
to eight binding motifs for the eight common HLA alleles;
this observation is consistent with previous descriptions of
these epitopes as potentially highly reactive T cell epitope
clusters for human T1D subjects and nondiabetic subjects
[23, 29]. Sixteen epitope clusters in human GAD65 with
strong binding motifs for DR4 and for at least four other HLA
were identified.
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Figure 7: Tregitope effect in TCR-transgenic mice. DO11.10 FoxP3/
GFP transgenic mice were immunized with mT167/mT289/IFA and
an irrelevant peptide HA (influenza hemagglutinin, Table 2) in
IFA. After 10 days, mice were sacrificed and assayed for (a) T cell
proliferation by in vitro culture with pOVA, and (b) FoxP3/GFP
(Tregs) expression by FACS after CD4 and KJ1-26 staining. Gamma
interferon expression in cell-culture supernatants was also suppressed (data not shown).

3.2. In Vitro Study Results: Epitope Prediction and Validation
3.2.1. GAD65 Epitope Prediction. We performed a detailed in
silico analysis of the islet cell antigen GAD65. As has been

3.2.2. HLA Binding Assays. Fourteen of the sixteen peptides
identified by EpiMatrix and ClustiMer were synthesized to a
purity of >80% and tested for binding affinity to DR4 by an
in vitro competition-based HLA binding assay as described
in Methods. In addition to performing HLA-DR4 binding
studies, we evaluated binding to a number of selected HLA
types. Among the fourteen epitopes predicted and synthesized, twelve were predicted to bind HLA-DR4. In the binding
assay for this allele, seven showed high affinity (IC50 <
25 𝜇M) while another two showed weak affinity (IC50 >
50 𝜇M), for a total of nine true positive predictions. The
remaining five peptides showed no DR4 affinity; two of these
five non-binders had EpiMatrix scores below the threshold
of significance, making them true negative predictions. Thus,
EpiMatrix accurately predicted the binding assay results for
eleven (79%) of the fourteen peptides. In our experience, lack
of binding can be observed for longer sequences which may
allow peptides to fold or aggregate in vitro, interfering with
HLA binding.
Additional HLA binding assays were performed to define
specific IC50 curves for binding to DRB1∗ 0101, DRB1∗ 0701,
and DRB1∗ 1501 (Table 1). Overall, when all EpiMatrix predictions (not just published HLA binding restrictions) are
included, the peptides bound as predicted for more than
90% of cases. EpiMatrix predicted and confirmed several new
HLA restrictions for the GAD65 DR4-restricted published
epitopes. For example, for peptide GAD65 243–267, affinity
for HLA-DR4 and numerous other alleles was predicted by
EpiMatrix and experimentally validated in binding assays.
GAD65 450–470 (Figure 3(a)), an unpublished epitope, also
bound promiscuously (as predicted).
3.2.3. Ex Vivo Assays with Human PBMC. We evaluated
human immune responses to the GAD65 peptides in the
presence or absence of Tregitopes. Subjects are described in
the methods section above. PBMCs from six DR4-positive
subjects and five non-diabetic subjects (Table 3) were examined for interferon gamma (IFN𝛾) secretion in response to
restimulation with individual GAD65 peptides after being
cultured with a pool of those peptides in the presence or
absence of hTregitope 167 and 289 by a two-step ELISpot assay
(described in Methods).
As shown in Table 3, seven of eleven subjects (64%)
demonstrated broad baseline immune responses to GAD65
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(with a number of spot-forming cells, or SFC, higher than 50
per 106 cells over background to at least half of the epitopes).
This is consistent with previously published results [23]. The
average number of GAD65 epitopes for which positive IFN𝛾
ELISpot responses were observed per T1D subject was 8.3
(Table 3). The average number of GAD65 epitopes for which
positive IFN𝛾 ELISpot responses were observed per normal
(non-diabetic) control subject was not significantly different
at 6.0 (Table 3). Thus, there were no clear differences observed
in terms of IFN𝛾-secreting cell numbers and epitope-specific
responses to GAD65 between diabetic and non-diabetic
groups, as has been previously observed [23].
All fourteen tested peptides derived from GAD65 and
selected using EpiMatrix induced significant IFN𝛾 responses
as measured by ELISpot in at least one of the tested subjects,
confirming the predictions. Of note, the EpiMatrix-selected
epitope GAD65 450–470 described in Figure 3 induced IFN𝛾
responses in PBMC from five of six (83%) of the diabetic
subjects and three of five (60%) negative control subjects;
immune responses to this peptide have not been previously
described in the literature.

cells over background) in the absence of Tregitopes. When
the degree of Tregitope suppression for the corresponding
assay, performed with Tregitopes, was evaluated by linear
regression analysis for the 42 peptide/subject pairs, no trend
was observed between higher iTEM scores for the Tregitope
peptide and the strength of the Tregitope effect. However,
regression analysis of the 16 cases where a statistically
significant suppression of the GAD65 immune response by
Tregitope was identified indicated a greater correlation (𝑃 <
0.01) between the Tregitope iTEM score and the strength
of the response to Tregitope (as measured by the actual
decrease in the number of SFC/106 cells). Specifically, higher
iTEM scores for these 16 peptide/patient combinations were
correlated with larger decreases in SFC/106 cells following
Tregitope co-incubation. The accuracy of the linear model,
as indicated by the 𝑅2 value, was greater for this data subset
(𝑅2 = 0.64) than for all the ELISpot results (𝑅2 = 0.07).
Thus the effect of individual Tregitopes based on HLA affinity
for the DR alleles of individual subjects was reaffirmed in the
present study [6].

3.2.4. Summary of Two-Step Assay Results. Following coincubation of GAD65 peptides with Tregitopes 167 and 289
with PBMC in vitro, there was a trend towards a reduction in
the recall response to the GAD65 peptides, although the inhibition levels varied significantly between patients and even
between peptides tested for a given patient. This variation
can be attributed to differences in the HLA affinity of the
GAD65 epitopes and the Tregitopes for an individual subject’s
HLA alleles (see iTEM analysis, Section 3.2.4). In terms
of ELISpot counts, as summarized in Table 4, Tregitopetreated PBMC mounted a diminished IFN𝛾 response to
78% (diabetic subjects) or 74% (normal control subjects)
of GAD65 epitopes included in each assay, as compared to
PBMC not pre-cultured with Tregitopes. Reductions in spot
counts were statistically significant (𝑃 < 0.05) for 26% of the
peptides tested.

3.2.6. Relationship between Tregitope Efficacy and Time from
Diagnosis. We reasoned that Tregitope effects might be more
pronounced early in the development of T1D, as the inflammatory responses to T1D antigens might be restricted to
fewer epitopes. Taking a closer look at two recently diagnosed
subjects, we found that subject 1107, diagnosed 7 months prior
to the blood draw, had fewer responses to GAD65 epitopes,
and those T cell responses that were present were lower and
more easily suppressed by coincubation with Tregitope than
in the other subjects. The onset of diabetes is difficult to
determine with precision; thus the strong baseline responses
and lack of Tregitope-mediated suppression in subject 1104
(Figure 8), who was diagnosed 6 months prior to blood
draw, may be an indicator that the subject had diabetes for a
substantial period of time before being medically diagnosed.

3.2.5. Individualized T Cell Epitope Measure (iTEM) and T1D
Responses. T cell responses to epitopes, whether T effector or
T regulatory, may vary depending on HLA binding affinity,
an effect that was previously described for Tregitopes [6]. We
have developed a method for predicting whether an immune
response (T effector or T regulatory) will be measured for
a given subject, based on the predicted binding affinity of
the study peptide for the subject’s HLA alleles, called the
individualized T cell epitope measure or iTEM [24]. Diabetic subjects’ IFN𝛾 ELISpot responses to GAD65 peptides
were significantly associated with iTEM scores for each
peptide by standard Chi-squared analysis (𝑃 < 0.005),
whereas no statistically significant relationship was identified
between iTEM scores and SFC for healthy control subjects
(𝑃 > 0.35). To determine if the effect of Tregitopes was
correlated with the iTEM score of the Tregitopes, iTEM scores
were calculated for the Tregitopes in the 42 peptide/subject
pairs for which the ELISpot showed a significant response
to GAD65 epitope restimulation (greater than 50 SFC/106

4. Discussion
4.1. In Vivo Studies. Novel therapies inducing long-lasting
islet-specific tolerance and protection are needed for T1D.
The critical period for intervention is at the onset of diabetes,
when Tregs can protect islet cell mass [30]. In the studies
described here, we demonstrated that co-administration of
Tregitopes and mPPI peptides prior to onset of diabetes led
to the abrogation of diabetes over a period of 15 to 20 weeks.
Diabetes was completely suppressed to the end of the study
(20 weeks) in mice treated with target antigens (mPPI) and
Tregitope; a moderate effect was observed for Tregitope alone,
and no effect was observed when mice were treated with
mPPI peptides and control peptide Tet Tox or with empty
liposomes.
In a therapeutic model also using NOD mice dosed with
mTregitopes 167 and 289 (and no additional target antigens),
we show that the administration of Tregitopes in IFA following onset of diabetes led to a significant reduction in the incidence of diabetes as compared to saline control. In a repeat
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Figure 8: ELISpot results from a recently diagnosed T1D patient. Dark bars represent cells preincubated with a pool of GAD65-derived
epitopes, and light bars represent cells precultured with the same pool plus Tregitope peptides. IFN𝛾 ELISpot responses to GAD65 peptides
incubated with PBMCs from a recently diagnosed subject (<6 months) were either low or did not meet criteria for a positive response.
Tregitopes were able to suppress responses to the whole GAD65 protein and to the GAD65 peptides, individually or pooled.

of this experiment, the duration of tolerance lasted longer
than 15 weeks after only a single treatment with Tregitopes.
4.1.1. Induction of Adaptive Tolerance. One potential explanation for the effect of Tregitopes in the NOD model would be
induction of islet-cell antigen-specific tolerance. To test this,
we evaluated the effect of Tregitope on antigen-specific
adaptive tolerance in an existing TCR-Tg mouse model. TCRTg FoxP3-expressing iTregs (GFP-fluorescent in this model)
were identified following treatment with mTregitopes 167 and
289 by gating on KJ1-26+ T cells (a marker for the Tg TCR).
Treatment with the control peptide Flu HA 306–318 did
not result in similar levels of iTregs. We also showed that these
Tregs were functional, in that OVA peptide-specific proliferative T cell responses were suppressed, as was cytokine expression. In a repeat experiment performed in Rag−/− DO11.10
mice (lacking nTregs), no Tregitope effect was observed, suggesting that the suppression of immune responses may
require induction and activation of Tregitope-specific cells,
which subsequently lead to modification of the phenotype of
the TCR Tg T cells. Thus, the study was entirely consistent
with a two-step model for adaptive tolerance induction by
Tregitopes: (i) induction of Tregitope-specific KJ1-26− (non
TCR-Tg) nTregs followed by (ii) induction of KJ1-26+ (TCR
Tg) iTregs. In mechanism of action studies (Cousens et al.,
submitted for publication), we have confirmed that incubation of Tregitope with T cells and APC leads to the following

chronological series of events: Treg expansion and activation,
followed by modification of the APC phenotype (at 72 hours),
which is in turn followed by induction of antigen-specific
adaptive tolerance.
Adaptive tolerance to islet cell antigens is believed to be a
key component to successful T1D therapy. The adaptive Treg
induction specific to the OVA peptide, following treatment
with Tregitopes, in DO11.10/FoxP3-GFP/TCR-Tg mice was
similar to the amount of iTreg induction observed to a
birch pollen antigen in our original published studies [6].
Moreover, van der Marel et al. delivered Tregitope 167
using an AAV in a mouse model of colitis and observed
significant reductions in disease endpoints [31]. Protection
from disease was associated with thymic Treg populations
that increased from 7% in control- to 11% in Tregitope-treated
mice. This provides independent evidence that even small
increases in Treg populations can have a significant effect
on the amelioration of inflammatory disease. Although Tregs
were initially thought to originate exclusively in the thymus
[32], subsequent studies in mice and humans showed that
CD4+ CD25hi FoxP3+ adaptive or induced Tregs can develop
in the periphery under a variety of conditions [2, 33].
4.2. In Vitro Studies
4.2.1. GAD65 Epitopes. Wicker et al. performed HLA DR4
binding assays using overlapping peptides from GAD65 and
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established that three high-binding peptides also stimulated
proliferative T cell responses in Tg mice expressing HLADRB1∗ 0401 [34]. A subsequent paper by Endl et al. confirmed
that peptides 266–285 and 556–575 were T cell epitopes in
diabetic subjects [35]; we confirmed these findings using
HLA DR4 analysis by EpiMatrix [36]. The three sequences
contain three of the top four GAD65 peptides selected by
EpiMatrix. Additional published GAD65 epitopes can be
found within the EpiMatrix-predicted clusters defined here.
We describe one new epitope located at GAD65 amino
acid 450 that has not been previously published. All of the
published epitopes were revalidated in HLA binding assays
and T cell assays, and one previously undiscovered epitope
was identified in this study, confirming the utility of epitopeprediction tools such as EpiMatrix and ClustiMer for use in
studies of autoimmunity. We found that type 1-diabetic and
normal control subject PBMC responded similarly to T1Dassociated antigens, as has been noted previously [23].
4.2.2. Two-Step Assays. When we co-incubated human Tregitopes with PBMC in vitro, we observed many instances in
which Tregitopes suppressed immune responses to epitopes
derived from GAD65. GAD65 epitope responses differed
by subject (as might be expected given HLA background),
and the effect of the Tregitopes also varied by the baseline
response to the GAD65 epitopes. In cases where the T cell response was stronger (more ELISpot-forming cells per million
PBMC) the Tregitopes generally did not suppress immune
responses. However, we did observe an overall correlation
with the iTEM score for the Tregitopes and the Tregitope
suppression in vitro. Although limited in terms of the number
of subjects and the number of immune responses observed,
the correlation between iTEM score (ability of the Tregitopes
to be presented in the context of the subjects’ HLA DR alleles)
and suppression of immune response in vitro is consistent
with previously published [6] and unpublished data (Federico
Mingozzi, personal communication).
Negative control wells contained medium alone; control
peptides were not used in these in vitro studies. Immune
responses seen in the subjects ranged from high to low for
each of the peptides. Nonetheless, in previously published
studies [6] and in studies submitted for publication (Cousens,
mechanism of action studies), there is no comparable suppressive effect of control (MHC-binding) peptide in vivo or
in vitro, as compared to Tregitopes, which have also been
shown to directly induce the expansion of Tregs. Tregitope
suppression was not due to toxicity, again, since global
immunosuppression was not seen and the in vitro suppressive
responses were highly correlated with the ability of the HLA
to present the peptide as defined by iTEM. In addition, no
toxicities were associated with Tregitope treatment in any of
the four NOD studies described here.

5. Conclusions
Reducing islet cell destruction and preserving islet cell
function are the goals of therapies intended to cure T1D.
Proposed treatments with anti-CD3 monoclonal antibodies
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(mAbs) such as Teplizumab, which induce Tregs, have shown
some efficacy, but the mechanism of Treg induction is elusive
and the effect appears to be either brief and/or requires
treatment very early in T1D disease [37]. The critical period
for intervention is at the onset of diabetes, when Tregs can
protect islet cell mass [30]. Treg function may also be better
preserved early in T1D. Similar drugs targeting effector T cells
such as Abatacept and Otelixizumab may also be of limited
efficacy, in part due to their lack of specificity for pathogenic
T cells. Tregitopes administered with T1D antigens may
induce antigen-specific tolerance and, for that reason, could
be more effective than previously studied tolerance-inducing
approaches.
Tregitopes administered to NOD mice at onset of diabetes
resolved hyperglycemia for as long as 29 weeks, and, in
parallel studies with DO11.10 Tg mice, Tregitope treatment
induced antigen-specific Tregs in these mice. Effective tolerance induction was achieved with a single dose of Tregitopes
in IFA, and, taken together, the in vivo studies suggest
that Tregitopes induce antigen-specific tolerance and that
Tregitopes might be effective for the initial (early) treatment
of T1D. Maintenance of tolerance might require intermittent
low-dose IL-2 to maintain Treg populations [38].
Tregitope therapy may be considered similar to, but
also distinct from, IVIG (polyclonal intravenous human
immunoglobulin G) therapy [39]. In a number of autoimmune disease conditions in animals and in humans, IVIG
has been shown to induce the expansion of Tregs and IL10 secretion [40–43]; dendritic cell processing is required for
the effect of IVIG in some studies [44]. Tregitopes are also
similar to a number of other IgG-derived peptides (independently identified as Tregitopes due to their fulfillment of
the standard Tregitope criteria) such as CDR1, also known
as Edratide [45–47], which provides additional independent
confirmation of Tregitopes. By inference from these human
studies, Tregitope peptides administered to humans may have
a safety profile similar to IVIG.
Two additional peptide immunotherapies that resemble
Tregitope in that they stimulate antigen-specific immunomodulatory T cell responses, GAD and DiaPep277, are in clinical
trials. Each of these is based on a single peptide or protein.
Unlike DiaPep, the Tregitope therapeutic strategy might
include multiple Tregitope peptides from IgG administered in
conjunction with islet cell antigens, which would enhance
Treg responses to those antigens. Similarly, GAD immunotherapy of T1D patients might be enhanced by the addition
of Tregitopes.
And finally, initial studies of Tregitope in murine transplant studies demonstrate that they may be effective against
chronic but not acute graft rejection (Nader Najafian, personal communication). Thus Tregitopes may also be of use
in the context of regenerative approaches to treating T1D
by increasing beta-cell mass and facilitating islet cell transplantation. Applications to other autoimmune diseases and
enzyme-replacement therapy are also being considered [48,
49]. Whether as part of a preventive, therapeutic, or transplant regimen, induction of tolerance to islet cell antigens
using Tregitopes could result in a paradigm shift in disease
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management, allowing clinicians to safely unlock the potential of Tregs to regulate immune responses and expand the
number of immunotherapeutic strategies available to treat
autoimmune diabetes.

Acknowledgments
This work was supported by a Juvenile Diabetes Research
Foundation “Industry Grant” and SBIR Phase I/II awards
(1/5R43DK081261) from the National Institute of Health. The
expert assistance of Ryan Tassone and editorial effort of
Lauren Levitz are gratefully acknowledged.

References
[1] S. A. Long, K. Cerosaletti, P. L. Bollyky et al., “Defects in IL2R signaling contribute to diminished maintenance of FOXP3
expression in CD4+CD25+ regulatory T-cells of type 1 diabetic
subjects,” Diabetes, vol. 59, no. 2, pp. 407–415, 2010.
[2] J. A. Bluestone and A. K. Abbas, “Natural versus adaptive regulatory T cells,” Nature Reviews Immunology, vol. 3, no. 3, pp.
253–257, 2003.
[3] M. Battaglia and M. G. Roncarolo, “Immune intervention with
T regulatory cells: past lessons and future perspectives for type
1 diabetes,” Seminars in Immunology, vol. 23, no. 3, pp. 182–194,
2011.
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